Zenas BioPharma, Inc.
ZBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.15B
Close$
$-2.30
108.4% downside
Current Fair Value
108.4% downsideOvervalued by 108.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.15 Billion |
|---|---|
| Enterprise Value | $1.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.44 |
| Beta | -0.69 |
| Outstanding Shares | 55,624,631 |
Return
| Return on Equity | -126.59% |
|---|---|
| Return on Assets | -56.86% |
| Return on Invested Capital | -37.19% |
Valuation & Multiples
| P/E Ratio | -2.84 |
|---|---|
| PEG | -2.01 |
| Price to Sales | - |
| Price to Book Ratio | 4.54 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.94 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | 1.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-1.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$15.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7680▲ 11.89% |
|---|---|
| Total Calls | 178,000▼ 33.68% |
| Total Puts | 136,700▼ 21.53% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 123.85%▲ 25.27% |
|---|---|
| Total Invested | $1.10B▼ 27.04% |
| Investors Holding | 144▲ 9.00% |
ESG Score
No data
About Zenas BioPharma, Inc.
130 employees
CEO: Mr. Leon Oliver Moulder Jr., M.B.A. Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibod...